Retrieve available abstracts of 98 articles: HTML format
Single Articles
July 2025
ROLFO C, O'Brate A, Menzel C, Bruns R, et al Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses
from the Phase II VISION Study of Tepotinib.
Clin Cancer Res. 2025;31:2675-2684. PubMedAbstract available
JANG HJ, Patel M, Wang DY, Kang SW, et al Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in
Pleural Mesothelioma.
Clin Cancer Res. 2025;31:2639-2654. PubMedAbstract available
June 2025
GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell
Lung Cancer Molecular Subtypes.
Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981. PubMedAbstract available
DAVAR D, Eroglu Z, Milhem M, Becerra C, et al Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or
Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806. PubMedAbstract available
DAVIES KD Finding Rearrangements in the Cell-Free DNA Haystack.
Clin Cancer Res. 2025;31:2264-2266. PubMedAbstract available
PAWELETZ CP, Urvalek A, Ha M, Garg K, et al Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method
for Limited Clinical Samples.
Clin Cancer Res. 2025;31:2406-2412. PubMedAbstract available
MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but
Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658. PubMedAbstract available
ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced
NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical
Trials.
Clin Cancer Res. 2025;31:2162-2172. PubMedAbstract available
May 2025
CHENG Y, Wang J, Yu Y, Wang Q, et al Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody,
in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022. PubMedAbstract available
April 2025
ZHANG J, Jin Y, Lin H, Deng J, et al Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor
microenvironment in small cell lung cancer.
Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399. PubMedAbstract available
HIRSCH FR Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and
the Biomarker?
Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839. PubMedAbstract available
ZHOU J, Muluneh B, Wang Z, Yao H, et al Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict
Survival in Non-Small-Cell Lung Cancer.
Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292. PubMedAbstract available
PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al Factors Associated with Disease Progression after Discontinuation of Immune
Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced
Non-Small Cell Lung Cancer.
Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990. PubMedAbstract available
JENG MY, Schoenfeld AJ Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
Clin Cancer Res. 2025;31:1381-1382. PubMedAbstract available
MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different
Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
Clin Cancer Res. 2025;31:1533-1545. PubMedAbstract available
March 2025
KANDA S, Niho S, Kurata T, Nomura S, et al Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated
Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR
Mutation.
Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3532. PubMedAbstract available
KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in
RET-Aberrant Cancers.
Clin Cancer Res. 2025;31:1127-1141. PubMedAbstract available
TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR
Mutated and Wild-Type Non-Small Cell Lung Cancer.
Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347. PubMedAbstract available
February 2025
CHENG H, Janakiram M, Borczuk A, Lin J, et al Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely
Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Clin Cancer Res. 2025;31:788. PubMed
WOJTALLA A, Fischer B, Kotelevets N, Mauri FA, et al Correction: Targeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell
Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.
Clin Cancer Res. 2025;31:787. PubMed
AGGARWAL RK, Sidoli S, Wang J, Sahu S, et al Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis
via IRAK4 Activation.
Clin Cancer Res. 2025;31:746-755. PubMedAbstract available
KOBOLD S RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
Clin Cancer Res. 2025;31:437-438. PubMedAbstract available
JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and
Epithelial Malignancies.
Clin Cancer Res. 2025;31:503-514. PubMedAbstract available
January 2025
CHIU CL, Zhang D, Zhao H, Wei Y, et al Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028. PubMedAbstract available
ZHANG JT, Liu SY, Gao X, Liu SM, et al Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in
Localized Non-Small Cell Lung Cancer.
Clin Cancer Res. 2025 Jan 24. doi: 10.1158/1078-0432.CCR-24-2909. PubMedAbstract available
KATO R, Solanki HS, Ozakinci H, Desai B, et al In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in
KRASG12C--mutant non-small cell lung cancer.
Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3714. PubMedAbstract available
CAPPUZZO F, Ricciuti B, Delmonte A, Bonanno L, et al MAPK pathway activating alteration and immunotherapy efficacy in squamous cell
lung carcinoma: results from the randomized, prospective SQUINT trial.
Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077. PubMedAbstract available
SMEENK MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally
advanced non-small cell lung cancer: the Induction trial.
Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476. PubMedAbstract available
ROSNER S, Connor S, Sanber K, Zahurak M, et al Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in
Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint
Blockade.
Clin Cancer Res. 2025;31:339-351. PubMedAbstract available
REINECKE JB, Jimenez Garcia L, Gross AC, Cam M, et al Aberrant Activation of Wound-Healing Programs within the Metastatic Niche
Facilitates Lung Colonization by Osteosarcoma Cells.
Clin Cancer Res. 2025;31:414-429. PubMedAbstract available
DALL'OLIO FG, Zrafi W, Roelants V, Ambrosini V, et al Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker
for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
Clin Cancer Res. 2025;31:352-364. PubMedAbstract available
NEGRAO MV, Paula AG, Molkentine D, Hover L, et al Impact of co-mutations and transcriptional signatures in non-small cell lung
cancer patients treated with adagrasib in the KRYSTAL-1 trial.
Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310. PubMedAbstract available
MEADOR CB, Digumarthy SR, Yeap BY, Hung YP, et al Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC:
Final Analysis and CNS Outcomes.
Clin Cancer Res. 2025;31:25-34. PubMedAbstract available
SCHULER M Facts and hopes in neoadjuvant immunotherapy combinations in resectable
non-small-cell lung cancer.
Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-1441. PubMedAbstract available
December 2024
LEE S, Hamid O, Jotte R, Zakharia Y, et al Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1
Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous
Melanoma.
Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478. PubMedAbstract available
AOKAGE K, Koyama S, Kumagai S, Nomura K, et al Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant
Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST
ENERGY).
Clin Cancer Res. 2024;30:5584-5592. PubMedAbstract available
SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and
Recommended Surveillance Strategies.
Clin Cancer Res. 2024;30:5681-5692. PubMedAbstract available
VON ITZSTEIN MS, Burns TF, Dowell JE, Horn L, et al Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated,
advanced KRAS mutant non-small cell lung cancer.
Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722. PubMedAbstract available
November 2024
ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot
Studies in Patients With Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591. PubMedAbstract available
SOO RA, Dafni U, Han JY, Cho BC, et al ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with
Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER
Trial.
Clin Cancer Res. 2024;30:5180-5191. PubMedAbstract available
October 2024
STEWART CA, Diao L, Xi Y, Wang R, et al YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular
Features and Therapeutic Vulnerabilities.
Clin Cancer Res. 2024;30:4743-4754. PubMedAbstract available
VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small
Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925. PubMedAbstract available
LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma
Metastasis.
Clin Cancer Res. 2024;30:4464-4481. PubMedAbstract available
September 2024
MORGENSZTERN D, Ready N, Johnson ML, Dowlati A, et al A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein
6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
Clin Cancer Res. 2024 Sep 17. doi: 10.1158/1078-0432.CCR-24-1547. PubMedAbstract available
VOKES NI, Le X, Yap TA PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated
NSCLC.
Clin Cancer Res. 2024;30:3968-3970. PubMedAbstract available
CHOI Y, Dharia NV, Jun T, Chang J, et al Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and
Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
Clin Cancer Res. 2024;30:3788-3797. PubMedAbstract available
EL ZARIF T, Meador CB, Qiu X, Seo JH, et al Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung
Adenocarcinoma through Epigenomic cfDNA Profiling.
Clin Cancer Res. 2024;30:3798-3811. PubMedAbstract available
August 2024
KOBAN MU, Hartmann M, Amexis G, Franco P, et al Targeted therapies, novel antibodies, and immunotherapies in advanced non-small
cell lung cancer: clinical evidence and drug approval patterns.
Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741. PubMedAbstract available
OH S, Koh J, Kim TM, Kim S, et al Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution
towards small cell lung cancer.
Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-0160. PubMedAbstract available
July 2024
REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in
Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC
Study.
Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013. PubMedAbstract available
SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance
in non-small cell lung cancer patient-derived tumor organoids.
Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980. PubMedAbstract available
SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al Transcriptional phenocopies of deleterious KEAP1 mutations correlate with
survival outcomes in lung cancer treated with immunotherapy.
Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626. PubMedAbstract available
YANG SR, Jayakumaran G, Benhamida J, Febres-Aldana CA, et al Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly
Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.
Clin Cancer Res. 2024;30:2780-2789. PubMedAbstract available
June 2024
CHOUDHURY NJ, Lai WV, Makhnin A, Heller G, et al A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in
combination with irinotecan in patients with recurrent small cell lung cancer.
Clin Cancer Res. 2024 Jun 28. doi: 10.1158/1078-0432.CCR-23-3383. PubMedAbstract available
BARBATO MI, Bradford D, Ren Y, Aungst SL, et al FDA Approval Summary: Repotrectinib for locally advanced or metastatic
ROS1-positive non-small cell lung cancer.
Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949. PubMedAbstract available
PANG L, Huang Y, Zhuang W, Zhang Y, et al Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the
Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
Clin Cancer Res. 2024;30:2636-2646. PubMedAbstract available
DALAL B, Tada T, Patel DP, Pine SR, et al Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung
Cancer in Non-smokers and Tobacco Smokers.
Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637. PubMedAbstract available
ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy
Results and Informs Value of Tissue Confirmation.
Clin Cancer Res. 2024;30:2452-2460. PubMedAbstract available
May 2024
FUKUDA A, Okuma Y From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR
Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035. PubMedAbstract available
PENG X, Zhao H, Ye L, Hou F, et al Biomarker identification and risk prediction model development for differentiated
thyroid carcinoma lung metastasis based on primary lesion proteomics.
Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806. PubMedAbstract available
REKHTMAN N All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient
Undifferentiated Tumors Masquerading as SCLC.
Clin Cancer Res. 2024;30:1708-1711. PubMedAbstract available
MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to
Concomitant PD-1 Blockade.
Clin Cancer Res. 2024;30:1833-1845. PubMedAbstract available
April 2024
ZHOU R, Liu F, Zhang H, Wang D, et al Fraction dose escalation of hypofractionated radiotherapy with concurrent
chemotherapy and subsequent consolidation immunotherapy in locally advanced
non-small cell lung cancer: a phase 1 study.
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600. PubMedAbstract available
ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al Facts and hopes on cancer immunotherapy for small cell lung cancer.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. PubMedAbstract available
PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al Spatially preserved multi-region transcriptomic subtyping and biomarkers of
chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104. PubMedAbstract available
GRAZINI U, Markovets A, Ireland L, O'Neill D, et al Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven
Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540. PubMedAbstract available
OH HJ, Bae SC, Oh IJ, Park CK, et al Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung
Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
Clin Cancer Res. 2024;30:1478-1487. PubMedAbstract available
LEE EJ, Oh SY, Lee YW, Kim JY, et al Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and
On-Target Resistance in NSCLC.
Clin Cancer Res. 2024;30:1582-1594. PubMedAbstract available
SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed
Human scFv Library.
Clin Cancer Res. 2024;30:1293-1306. PubMedAbstract available
VAIDYA P, Cohen EEW Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging
Evidence.
Clin Cancer Res. 2024;30:1232-1239. PubMedAbstract available
February 2024
ZHOU I, Plana D, Palmer AC Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Clin Cancer Res. 2024;30:786-792. PubMedAbstract available
KASI PM, Lee JK, Pasquina LW, Decker B, et al Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and
Rearrangements Across Cancer Types.
Clin Cancer Res. 2024;30:836-848. PubMedAbstract available
WEI D, Wang L, Zuo X, Maitra A, et al A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in
Pancreatic Cancer.
Clin Cancer Res. 2024;30:655-662. PubMedAbstract available
WANG H, Chen Y, Wang X, Huang B, et al Germline mutations of Holliday junction resolvase genes in multiple primary
malignancies involving lung cancer lead to PARP inhibitor sensitization.
Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300. PubMedAbstract available
VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al Combining genomic biomarkers to guide immunotherapy in non-small cell lung
cancer.
Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027. PubMedAbstract available
LAKHANI NJ, Rasco D, Wang H, Men L, et al First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax
in Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res. 2024;30:506-521. PubMedAbstract available
January 2024
PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al Multi-omics analysis reveals immune features associated with immunotherapy
benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I
trial.
Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251. PubMedAbstract available
GUAN S, Chen X, Wei Y, Wang F, et al Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3
expression in non-small cell lung cancer patients.
Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357. PubMedAbstract available
KESARI S, Wagle N, Carrillo JA, Sharma A, et al Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
Clin Cancer Res. 2024;30:323-333. PubMedAbstract available
NG J, Cai L, Girard L, Prall OWJ, et al Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung
Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360. PubMedAbstract available
NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al Phase II study of durvalumab immediately after completion of chemoradiotherapy in
unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568. PubMedAbstract available
December 2023
LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al Objective analysis and clinical significance of the spatial tumor infiltrating
lymphocyte patterns in non-small cell lung cancer (NSCLC).
Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457. PubMedAbstract available
PASSIGLIA F, Righi L, Bironzo P, Listi A, et al Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer
harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective
trial.
Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431. PubMedAbstract available
BOUMELHA J, Molina-Arcas M, Downward J Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Clin Cancer Res. 2023;29:5012-5020. PubMedAbstract available
HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al A dysfunctional T cell gene signature for predicting non-response to PD-1
blockade in non-small cell lung cancer that is suitable for routine clinical
diagnostics.
Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061. PubMedAbstract available
ROLFO C, Russo A In search of lost biomarker for immunotherapy in small-cell lung cancer.
Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087. PubMedAbstract available
BESSEDE A, Peyraud F, Besse B, Cousin S, et al TROP2 is associated with primary resistance to immune checkpoint inhibition in
patients with advanced non-small cell lung cancer.
Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566. PubMedAbstract available
VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic
Vulnerabilities in NSCLC.
Clin Cancer Res. 2023;29:4958-4972. PubMedAbstract available
November 2023
MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al Elucidating the heterogeneity of immunotherapy response and immune-related
toxicities by longitudinal ctDNA and immune cell compartment tracking in lung
cancer.
Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469. PubMedAbstract available
October 2023
HERBST RS, Blanke CD, Sigal EV Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of
Public-Private Partnerships.
Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. PubMedAbstract available
PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung
cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational
burden.
Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689. PubMedAbstract available
September 2023
BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary
lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928. PubMedAbstract available
DIMOU A Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152. PubMedAbstract available
SOLTA A, Boettiger K, Kovacs I, Lang C, et al Entinostat enhances the efficacy of chemotherapy in small cell lung cancer
through S-phase arrest and decreased base excision repair.
Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795. PubMedAbstract available
CANTOR DJ, Aggarwal C Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
Clin Cancer Res. 2023;29:3563-3565. PubMedAbstract available
DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET
Fusion-Positive Solid Tumors.
Clin Cancer Res. 2023;29:3573-3578. PubMedAbstract available
ABEL ML, Takahashi N, Peer C, Redon CE, et al Targeting Replication Stress and Chemotherapy Resistance with a Combination of
Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Clin Cancer Res. 2023;29:3603-3611. PubMedAbstract available
PELLINI B, Madison RW, Childress M, Miller ST, et al Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification
in Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578. PubMedAbstract available